These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8738056)

  • 1. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease.
    Linde T; Wikström B; Andersson LG; Danielson BG
    Scand J Urol Nephrol; 1996 Apr; 30(2):115-20. PubMed ID: 8738056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin.
    Teruel JL; Pascual J; Jiménez M; Liaño F; Rivera M; Martínez J; Moya JL; Ortuño J
    Nephron; 1991; 58(2):135-7. PubMed ID: 1865967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients.
    Fernández A; Vega N; Jiménez F; Macía M; Laraudiogoitía E; Hortal L; Perdomo M; Plaza C; Rodríguez JC; Palop L
    Am J Nephrol; 1992; 12(4):207-11. PubMed ID: 1481867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin.
    Nonnast-Daniel B; Schäffer J; Frei U
    Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.
    Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J
    Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
    Morris KP; Skinner JR; Hunter S; Coulthard MG
    Arch Dis Child; 1993 May; 68(5):644-8. PubMed ID: 8323333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin.
    Abdulhadi MH; Fouad-Tarazi FM; Thomas T; Bravo EL; Paganini EP
    Nephrol Dial Transplant; 1990; 5 Suppl 1():102-8. PubMed ID: 2129437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia.
    Landgraf H; Grützmacher P; Garcia-Bartels C; Bergmann M; Ehrly AM; Schoeppe W
    Eur J Med; 1993; 2(7):393-7. PubMed ID: 8258026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin.
    Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA
    Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
    Portolés J; Torralbo A; Martin P; Rodrigo J; Herrero JA; Barrientos A
    Am J Kidney Dis; 1997 Apr; 29(4):541-8. PubMed ID: 9100042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients.
    Onoyama K; Kumagai H; Takeda K; Shimamatsu K; Fujishima M
    Nephrol Dial Transplant; 1989; 4(11):966-70. PubMed ID: 2516888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating haematopoietic progenitors during treatment of renal anaemia with recombinant human erythropoietin.
    Göbel V; Hoffmann HG; Müller-Wiefel DE; Braun A; Ludwig R; Schärer K; Debatin KM
    Eur J Pediatr; 1994 Jan; 153(1):43-8. PubMed ID: 8313924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.
    Kampf D; Eckardt KU; Fischer HC; Schmalisch C; Ehmer B; Schostak M
    Nephron; 1992; 61(4):393-8. PubMed ID: 1501734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin.
    Kamata K; Marumo F; Onoyama K
    Jpn Circ J; 1991 Jul; 55(7):649-56. PubMed ID: 1880896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
    Frei U; Nonnast-Daniel B; Schäffer J; Koch KM
    Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.